At a glance
ClinicalIndex Comparison RecordPhase 2Unknown· 67 enrolled
Drug / intervention
Fulvestrantdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Phase II Study of Faslodex ? in Recurrent/Metastatic Endometrial Carcinoma
In Brief
A Phase 2 clinical trial evaluating Fulvestrant for Recurrent Uterine Corpus Carcinoma and 2 related conditions. Targeting 67 participants.
Detailed Summary
This phase II trial is studying fulvestrant to see how well it works in treating patients with recurrent, persistent, or metastatic endometrial cancer. Estrogen can stimulate the growth of cancer cells. Hormone therapy using fulvestrant may fight cancer by blocking the uptake of estrogen by the tumor cells.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsRecurrent Uterine Corpus Carcinoma, Stage III Uterine Corpus Cancer AJCC v7, Stage IV Uterine Corpus Cancer AJCC v7
Countries--
CollaboratorsNational Cancer Institute (NCI)
Timeline
Phase 2UnknownOverdue
2003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedJan 2003
Enrollment StartAug 2004
Primary CompletionMar 2008
TodayJul 2026
First PostedJan 27, 2003
Enrollment StartAug 30, 2004
Primary CompletionMar 17, 2008
TodayJul 2, 2026
Enrollment to primary: 3.5 yearsPosted 23.4 years ago
Interventions
Fulvestrantdrug
Given intramuscularly